上海医药：2024年中报点评：业绩符合预期；CSO业务增速显著

研究报告 Research Report 2 Sep 2024 上海医药 SH Pharma (2607 HK) 2024 年中报点评：业绩符合预期；CSO 业务增速显著 1H24 results largely in line; Significant growth in CSO business [Table_yemei 观点聚焦 1] Investment Focus | --- | --- | |----------------------------------------------------------------|------------------------| | | | | [Table_Info] 维持优于大市 Maintain OUTPERFORM | | | 评级 | 优于大市 OUTPERFORM | | 现价 | HK$10.80 | | 目标价 | HK$13.82 | | HTI ESG | 4.2-4.4-3.0 | | E-S-G: 0-5, (Please refer to the Appendix for ESG comments) | | | 市值 | HK$4 ...